Herpes Labialis
Conditions
Brief summary
A randomized study comparing the combination of valacyclovir and temovate gel (clobetasol gel) versus placebo for the treatment of recurrent herpes labialis (cold sores).
Detailed description
Herpes simplex labialis is a common, worldwide affliction for which neither public health procedures, vaccines, nor antiviral chemotherapy have had a major impact. The present study has been proposed because it has become clear there are marked limitations to the benefit of antiviral therapy in herpes labialis. Recently, a pilot trial of the combination of famciclovir and topical 0.05% fluocinonide vs famciclovir alone showed that the addition of corticosteroids to the antiviral drug treatment caused a marked and statistically significant reduction in lesion size and a trend to more aborted lesions. This study is designed as a randomized, placebo-controlled, , patient-initiated study. The objective of this study is to evaluate the safety and efficacy of oral valacyclovir 2grams BID for one day and topical temovate 0.05% gel BID for three days compared to placebo capsules and placebo gel in the episodic treatment of a single episode of recurrent herpes labialis in immunologically normal patients. Subjects will be screened, randomized to study drug and instructed to start using study drug within one hour of the first sign or symptom of their next episode of herpes labialis. Data on the treated lesion will be collected by clinic visits and a patient diary card.
Interventions
DRUGvalacyclovir+clobetasol gel
Sponsors
GlaxoSmithKline
University of Utah
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Age 18 years or older. * A history typical for recurrent herpes labialis. The subject must have experienced three or more cold sores in the last 12 months. * In general good health, without other serious medical conditions, as determined by the patient's account of his/her medical history. * Signature on the informed consent document.
Exclusion criteria
* Patients who have participated in an investigational drug study in the four-week period prior to enrollment. * Previous herpes vaccine at any time. * Patients with major medical conditions such as chronic heart, pulmonary, renal or hepatic diseases. * Patients with immunodeficiency disorders such as HIV infection or cancer chemotherapy. * Patients using topical steroids on or near the face or systemic steroids within 30 days of enrollment. * Women who are pregnant, lactating or breast feeding. * Women of childbearing potential not using adequate contraception as judged by the Investigator. * Recent history of alcohol or drug abuse, which in the opinion of the investigator, may interfere with that study patient's compliance with study requirements. * Significant skin disease such as atopic dermatitis, acne, or rosacea that would interfere with the assessment of lesions. * Allergy or hypersensitivity to steroids, acyclovir, penciclovir and/or other nucleoside analogues. * Subjects with impaired renal function as defined as a serum creatinine above the upper limits of normal.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary efficacy variable is the maximum size of the primary lesion complex | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary variables include: the proportion of primary lesions that are aborted; the mean time to healing of the primary lesion complex the frequency and mean duration of lesion pain among primary lesions; the frequency of secondary lesions | — |
Countries
United States
Outcome results
None listed